Who are the key players in the peptide cdmo market?

The peptide CDMO market size is expected to surge ahead in the coming years. Key drivers of the peptide CDMO market include the growing application of peptides in drugs and clinical trials. The rising R&D initiatives by pharmaceutical companies on peptide drug therapies for treating chronic diseases will spur the demand for the peptide CDMO market in the upcoming years. The outsourcing of peptide production to CDMOs for achieving flexibility and enhanced efficiency by drug companies will augment the market growth during the forecast period. The potential usage in the cosmetics industry will augment the market in the future.

Trends Influencing the Global Petide CDMO Market

Clinical trials of peptide drugs are in full swing

Peptides have gained considerable attention in recent years. The challenges in peptide synthesis and purification have been eliminated with the development of pharmaceutical peptides. The efficacy in treating type 2 diabetes and obesity has increased the commercial aspects of peptide treatment procedures. This has led to the development of several drugs currently under the pipeline. These factors will augment the growth of the peptide CDMO market during the forecast period.

Rise of therapeutic peptide treatments

Peptide drugs form a significant portion of the pharmaceutical industry. There are vigorous research and development activities and it is showing great promise in treating neurodegenerative diseases, diabetes, certain cancers, cardiovascular and infectious problems. These drugs are highly specific and bind to cell surface receptors to trigger intracellular immune responses. The production costs are cheaper. This is expected to spur the demand for the peptide CDMO market in the upcoming years.

Outsourcing to CDMOs

The development of new therapeutics is on a rise due to the growing disease burden on the healthcare sector. Peptide manufacturing requires specialized knowledge and technology to deliver quality products at affordable prices. There are techniques involved including chromatography. This provides a potential opportunity for CDMOs to expand their services and focus on analytical methods to deliver superior drugs. These will provide lucrative opportunities for the Peptide CDMO market growth during the forecasted period.

Use in cosmetics

The cosmetics industry is gaining interest in peptides. These molecules have the capacity to increase the skin barrier layer, decrease premature skin aging, and protect against harmful UV rays. They also help in moisturizing and provide anti-inflammatory properties which eliminate acne and irritation. These potential benefits will surge the growth of the peptide CDMO market during the forthcoming period.

Petide CDMO Market Share

Based on region, Asia-pacific is expected to grow in the peptide CDMO market share due to government funding in R&D initiatives and rising chronic diseases.

By Type

LPPS
SPPS
Mixed Phase

By Application

Pharmaceutical Industry
Cosmetics Industry
Others

By Company

Thermo Fisher Pharma
PolyPeptide
Bachem
ScinoPharm
CBL
AmbioPharm
Piramal Pharma
CordenPharma
CPC SCIENTIFIC
Provepharm
Space Peptides
Biopeptek
Alpha Biophama
Alabiochem
Aurigene Pharmaceutical Services
Chengdu Shengnuo Biotechnology Co., Ltd
Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd

By Region

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

FEATURED COMPANIES

Aurigene Pharmaceutical Services

Chengdu Shengnuo Biotechnology Co., Ltd

Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd

1 Report Business Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Peptide CDMO Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 LPPS

1.2.3 SPPS

1.2.4 Mixed Phase

1.3 Market by Application

1.3.1 Global Peptide CDMO Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Pharmaceutical Industry

1.3.3 Cosmetics Industry

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Peptide CDMO Market Perspective (2017-2028)

2.2 Peptide CDMO Growth Trends by Region

2.2.1 Peptide CDMO Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Peptide CDMO Historic Market Size by Region (2017-2022)

2.2.3 Peptide CDMO Forecasted Market Size by Region (2023-2028)

2.3 Peptide CDMO Market Dynamics

2.3.1 Peptide CDMO Industry Trends

2.3.2 Peptide CDMO Market Drivers

2.3.3 Peptide CDMO Market Challenges

2.3.4 Peptide CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peptide CDMO Players by Revenue

3.1.1 Global Top Peptide CDMO Players by Revenue (2017-2022)

3.1.2 Global Peptide CDMO Revenue Market Share by Players (2017-2022)

3.2 Global Peptide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Peptide CDMO Revenue

3.4 Global Peptide CDMO Market Concentration Ratio

3.4.1 Global Peptide CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peptide CDMO Revenue in 2021

3.5 Peptide CDMO Key Players Head office and Area Served

3.6 Key Players Peptide CDMO Product Solution and Service

3.7 Date of Enter into Peptide CDMO Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Peptide CDMO Breakdown Data by Type

4.1 Global Peptide CDMO Historic Market Size by Type (2017-2022)

4.2 Global Peptide CDMO Forecasted Market Size by Type (2023-2028)

5 Peptide CDMO Breakdown Data by Application

5.1 Global Peptide CDMO Historic Market Size by Application (2017-2022)

5.2 Global Peptide CDMO Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Peptide CDMO Market Size (2017-2028)

6.2 North America Peptide CDMO Market Size by Type

6.2.1 North America Peptide CDMO Market Size by Type (2017-2022)

6.2.2 North America Peptide CDMO Market Size by Type (2023-2028)

6.2.3 North America Peptide CDMO Market Share by Type (2017-2028)

6.3 North America Peptide CDMO Market Size by Application

6.3.1 North America Peptide CDMO Market Size by Application (2017-2022)

6.3.2 North America Peptide CDMO Market Size by Application (2023-2028)

6.3.3 North America Peptide CDMO Market Share by Application (2017-2028)

6.4 North America Peptide CDMO Market Size by Country

6.4.1 North America Peptide CDMO Market Size by Country (2017-2022)

6.4.2 North America Peptide CDMO Market Size by Country (2023-2028)

6.4.3 U.S.

6.4.4 Canada

7 Europe

7.1 Europe Peptide CDMO Market Size (2017-2028)

7.2 Europe Peptide CDMO Market Size by Type

7.2.1 Europe Peptide CDMO Market Size by Type (2017-2022)

7.2.2 Europe Peptide CDMO Market Size by Type (2023-2028)

7.2.3 Europe Peptide CDMO Market Share by Type (2017-2028)

7.3 Europe Peptide CDMO Market Size by Application

7.3.1 Europe Peptide CDMO Market Size by Application (2017-2022)

7.3.2 Europe Peptide CDMO Market Size by Application (2023-2028)

7.3.3 Europe Peptide CDMO Market Share by Application (2017-2028)

7.4 Europe Peptide CDMO Market Size by Country

7.4.1 Europe Peptide CDMO Market Size by Country (2017-2022)

7.4.2 Europe Peptide CDMO Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Peptide CDMO Market Size (2017-2028)

8.2 Asia-Pacific Peptide CDMO Market Size by Type

8.2.1 Asia-Pacific Peptide CDMO Market Size by Type (2017-2022)

8.2.2 Asia-Pacific Peptide CDMO Market Size by Type (2023-2028)

8.2.3 Asia-Pacific Peptide CDMO Market Share by Type (2017-2028)

8.3 Asia-Pacific Peptide CDMO Market Size by Application

8.3.1 Asia-Pacific Peptide CDMO Market Size by Application (2017-2022)

8.3.2 Asia-Pacific Peptide CDMO Market Size by Application (2023-2028)

8.3.3 Asia-Pacific Peptide CDMO Market Share by Application (2017-2028)

8.4 Asia-Pacific Peptide CDMO Market Size by Region

8.4.1 Asia-Pacific Peptide CDMO Market Size by Region (2017-2022)

8.4.2 Asia-Pacific Peptide CDMO Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9 Latin America

9.1 Latin America Peptide CDMO Market Size (2017-2028)

9.2 Latin America Peptide CDMO Market Size by Type

9.2.1 Latin America Peptide CDMO Market Size by Type (2017-2022)

9.2.2 Latin America Peptide CDMO Market Size by Type (2023-2028)

9.2.3 Latin America Peptide CDMO Market Share by Type (2017-2028)

9.3 Latin America Peptide CDMO Market Size by Application

9.3.1 Latin America Peptide CDMO Market Size by Application (2017-2022)

9.3.2 Latin America Peptide CDMO Market Size by Application (2023-2028)

9.3.3 Latin America Peptide CDMO Market Share by Application (2017-2028)

9.4 Latin America Peptide CDMO Market Size by Country

9.4.1 Latin America Peptide CDMO Market Size by Country (2017-2022)

9.4.2 Latin America Peptide CDMO Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peptide CDMO Market Size (2017-2028)

10.2 Middle East & Africa Peptide CDMO Market Size by Type

10.2.1 Middle East & Africa Peptide CDMO Market Size by Type (2017-2022)

10.2.2 Middle East & Africa Peptide CDMO Market Size by Type (2023-2028)

10.2.3 Middle East & Africa Peptide CDMO Market Share by Type (2017-2028)

10.3 Middle East & Africa Peptide CDMO Market Size by Application

10.3.1 Middle East & Africa Peptide CDMO Market Size by Application (2017-2022)

10.3.2 Middle East & Africa Peptide CDMO Market Size by Application (2023-2028)

10.3.3 Middle East & Africa Peptide CDMO Market Share by Application (2017-2028)

10.4 Middle East & Africa Peptide CDMO Market Size by Country

10.4.1 Middle East & Africa Peptide CDMO Market Size by Country (2017-2022)

10.4.2 Middle East & Africa Peptide CDMO Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11 Key Players Profiles

11.1 Thermo Fisher Pharma

11.1.1 Thermo Fisher Pharma Company Details

11.1.2 Thermo Fisher Pharma Business Overview

11.1.3 Thermo Fisher Pharma Peptide CDMO Introduction

11.1.4 Thermo Fisher Pharma Revenue in Peptide CDMO Business (2017-2022)

11.1.5 Thermo Fisher Pharma Recent Developments

11.2 PolyPeptide

11.2.1 PolyPeptide Company Details

11.2.2 PolyPeptide Business Overview

11.2.3 PolyPeptide Peptide CDMO Introduction

11.2.4 PolyPeptide Revenue in Peptide CDMO Business (2017-2022)

11.2.5 PolyPeptide Recent Developments

11.3 Bachem

11.3.1 Bachem Company Details

11.3.2 Bachem Business Overview

11.3.3 Bachem Peptide CDMO Introduction

11.3.4 Bachem Revenue in Peptide CDMO Business (2017-2022)

11.3.5 Bachem Recent Developments

11.4 ScinoPharm

11.4.1 ScinoPharm Company Details

11.4.2 ScinoPharm Business Overview

11.4.3 ScinoPharm Peptide CDMO Introduction

11.4.4 ScinoPharm Revenue in Peptide CDMO Business (2017-2022)

11.4.5 ScinoPharm Recent Developments

11.5 CBL

11.5.1 CBL Company Details

11.5.2 CBL Business Overview

11.5.3 CBL Peptide CDMO Introduction

11.5.4 CBL Revenue in Peptide CDMO Business (2017-2022)

11.5.5 CBL Recent Developments

11.6 AmbioPharm

11.6.1 AmbioPharm Company Details

11.6.2 AmbioPharm Business Overview

11.6.3 AmbioPharm Peptide CDMO Introduction

11.6.4 AmbioPharm Revenue in Peptide CDMO Business (2017-2022)

11.6.5 AmbioPharm Recent Developments

11.7 Piramal Pharma

11.7.1 Piramal Pharma Company Details

11.7.2 Piramal Pharma Business Overview

11.7.3 Piramal Pharma Peptide CDMO Introduction

11.7.4 Piramal Pharma Revenue in Peptide CDMO Business (2017-2022)

11.7.5 Piramal Pharma Recent Developments

11.8 CordenPharma

11.8.1 CordenPharma Company Details

11.8.2 CordenPharma Business Overview

11.8.3 CordenPharma Peptide CDMO Introduction

11.8.4 CordenPharma Revenue in Peptide CDMO Business (2017-2022)

11.8.5 CordenPharma Recent Developments

11.9 CPC SCIENTIFIC

11.9.1 CPC SCIENTIFIC Company Details

11.9.2 CPC SCIENTIFIC Business Overview

11.9.3 CPC SCIENTIFIC Peptide CDMO Introduction

11.9.4 CPC SCIENTIFIC Revenue in Peptide CDMO Business (2017-2022)

11.9.5 CPC SCIENTIFIC Recent Developments

11.10 Provepharm

11.10.1 Provepharm Company Details

11.10.2 Provepharm Business Overview

11.10.3 Provepharm Peptide CDMO Introduction

11.10.4 Provepharm Revenue in Peptide CDMO Business (2017-2022)

11.10.5 Provepharm Recent Developments

11.11 Space Peptides

11.11.1 Space Peptides Company Details

11.11.2 Space Peptides Business Overview

11.11.3 Space Peptides Peptide CDMO Introduction

11.11.4 Space Peptides Revenue in Peptide CDMO Business (2017-2022)

11.11.5 Space Peptides Recent Developments

11.12 Biopeptek

11.12.1 Biopeptek Company Details

11.12.2 Biopeptek Business Overview

11.12.3 Biopeptek Peptide CDMO Introduction

11.12.4 Biopeptek Revenue in Peptide CDMO Business (2017-2022)

11.12.5 Biopeptek Recent Developments

11.13 Alpha Biophama

11.13.1 Alpha Biophama Company Details

11.13.2 Alpha Biophama Business Overview

11.13.3 Alpha Biophama Peptide CDMO Introduction

11.13.4 Alpha Biophama Revenue in Peptide CDMO Business (2017-2022)

11.13.5 Alpha Biophama Recent Developments

11.14 Alabiochem

11.14.1 Alabiochem Company Details

11.14.2 Alabiochem Business Overview

11.14.3 Alabiochem Peptide CDMO Introduction

11.14.4 Alabiochem Revenue in Peptide CDMO Business (2017-2022)

11.14.5 Alabiochem Recent Developments

11.15 Aurigene Pharmaceutical Services

11.15.1 Aurigene Pharmaceutical Services Company Details

11.15.2 Aurigene Pharmaceutical Services Business Overview

11.15.3 Aurigene Pharmaceutical Services Peptide CDMO Introduction

11.15.4 Aurigene Pharmaceutical Services Revenue in Peptide CDMO Business (2017-2022)

11.15.5 Aurigene Pharmaceutical Services Recent Developments

11.16 Chengdu Shengnuo Biotechnology Co., Ltd

11.16.1 Chengdu Shengnuo Biotechnology Co., Ltd Company Details

11.16.2 Chengdu Shengnuo Biotechnology Co., Ltd Business Overview

11.16.3 Chengdu Shengnuo Biotechnology Co., Ltd Peptide CDMO Introduction

11.16.4 Chengdu Shengnuo Biotechnology Co., Ltd Revenue in Peptide CDMO Business (2017-2022)

11.16.5 Chengdu Shengnuo Biotechnology Co., Ltd Recent Developments

11.17 Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd

11.17.1 Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Company Details

11.17.2 Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Business Overview

11.17.3 Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Peptide CDMO Introduction

11.17.4 Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Revenue in Peptide CDMO Business (2017-2022)

11.17.5 Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Aurigene Pharmaceutical Services

Chengdu Shengnuo Biotechnology Co., Ltd

Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd

List of Tables

Table 1. Global Peptide CDMO Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

Table 2. Key Players of LPPS

Table 3. Key Players of SPPS

Table 4. Key Players of Mixed Phase

Table 5. Global Peptide CDMO Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

Table 6. Global Peptide CDMO Market Size by Region (US$ Million): 2017 VS 2021 VS 2028

Table 7. Global Peptide CDMO Market Size by Region (2017-2022) & (US$ Million)

Table 8. Global Peptide CDMO Market Share by Region (2017-2022)

Table 9. Global Peptide CDMO Forecasted Market Size by Region (2023-2028) & (US$ Million)

Table 10. Global Peptide CDMO Market Share by Region (2023-2028)

Table 11. Peptide CDMO Market Trends

Table 12. Peptide CDMO Market Drivers

Table 13. Peptide CDMO Market Challenges

Table 14. Peptide CDMO Market Restraints

Table 15. Global Peptide CDMO Revenue by Players (2017-2022) & (US$ Million)

Table 16. Global Peptide CDMO Revenue Share by Players (2017-2022)

Table 17. Global Top Peptide CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO as of 2021)

Table 18. Ranking of Global Top Peptide CDMO Companies by Revenue (US$ Million) in 2021

Table 19. Global 5 Largest Players Market Share by Peptide CDMO Revenue (CR5 and HHI) & (2017-2022)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Peptide CDMO Product Solution and Service

Table 22. Date of Enter into Peptide CDMO Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Peptide CDMO Market Size by Type (2017-2022) & (US$ Million)

Table 25. Global Peptide CDMO Revenue Market Share by Type (2017-2022)

Table 26. Global Peptide CDMO Forecasted Market Size by Type (2023-2028) & (US$ Million)

Table 27. Global Peptide CDMO Revenue Market Share by Type (2023-2028)

Table 28. Global Peptide CDMO Market Size by Application (2017-2022) & (US$ Million)

Table 29. Global Peptide CDMO Revenue Share by Application (2017-2022)

Table 30. Global Peptide CDMO Forecasted Market Size by Application (2023-2028) & (US$ Million)

Table 31. Global Peptide CDMO Revenue Share by Application (2023-2028)

Table 32. North America Peptide CDMO Market Size by Type (2017-2022) & (US$ Million)

Table 33. North America Peptide CDMO Market Size by Type (2023-2028) & (US$ Million)

Table 34. North America Peptide CDMO Market Size by Application (2017-2022) & (US$ Million)

Table 35. North America Peptide CDMO Market Size by Application (2023-2028) & (US$ Million)

Table 36. North America Peptide CDMO Market Size by Country (2017-2022) & (US$ Million)

Table 37. North America Peptide CDMO Market Size by Country (2023-2028) & (US$ Million)

Table 38. Europe Peptide CDMO Market Size by Type (2017-2022) & (US$ Million)

Table 39. Europe Peptide CDMO Market Size by Type (2023-2028) & (US$ Million)

Table 40. Europe Peptide CDMO Market Size by Application (2017-2022) & (US$ Million)

Table 41. Europe Peptide CDMO Market Size by Application (2023-2028) & (US$ Million)

Table 42. Europe Peptide CDMO Market Size by Country (2017-2022) & (US$ Million)

Table 43. Europe Peptide CDMO Market Size by Country (2023-2028) & (US$ Million)

Table 44. Asia Pacific Peptide CDMO Market Size by Type (2017-2022) & (US$ Million)

Table 45. Asia Pacific Peptide CDMO Market Size by Type (2023-2028) & (US$ Million)

Table 46. Asia Pacific Peptide CDMO Market Size by Application (2017-2022) & (US$ Million)

Table 47. Asia Pacific Peptide CDMO Market Size by Application (2023-2028) & (US$ Million)

Table 48. Asia Pacific Peptide CDMO Market Size by Region (2017-2022) & (US$ Million)

Table 49. Asia Pacific Peptide CDMO Market Size by Region (2023-2028) & (US$ Million)

Table 50. Latin America Peptide CDMO Market Size by Type (2017-2022) & (US$ Million)

Table 51. Latin America Peptide CDMO Market Size by Type (2023-2028) & (US$ Million)

Table 52. Latin America Peptide CDMO Market Size by Application (2017-2022) & (US$ Million)

Table 53. Latin America Peptide CDMO Market Size by Application (2023-2028) & (US$ Million)

Table 54. Latin America Peptide CDMO Market Size by Country (2017-2022) & (US$ Million)

Table 55. Latin America Peptide CDMO Market Size by Country (2023-2028) & (US$ Million)

Table 56. Middle East and Africa Peptide CDMO Market Size by Type (2017-2022) & (US$ Million)

Table 57. Middle East and Africa Peptide CDMO Market Size by Type (2023-2028) & (US$ Million)

Table 58. Middle East and Africa Peptide CDMO Market Size by Application (2017-2022) & (US$ Million)

Table 59. Middle East and Africa Peptide CDMO Market Size by Application (2023-2028) & (US$ Million)

Table 60. Middle East and Africa Peptide CDMO Market Size by Country (2017-2022) & (US$ Million)

Table 61. Middle East and Africa Peptide CDMO Market Size by Country (2023-2028) & (US$ Million)

Table 62. Thermo Fisher Pharma Company Details

Table 63. Thermo Fisher Pharma Business Overview

Table 64. Thermo Fisher Pharma Peptide CDMO Product

Table 65. Thermo Fisher Pharma Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 66. Thermo Fisher Pharma Recent Developments

Table 67. PolyPeptide Company Details

Table 68. PolyPeptide Business Overview

Table 69. PolyPeptide Peptide CDMO Product

Table 70. PolyPeptide Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 71. PolyPeptide Recent Developments

Table 72. Bachem Company Details

Table 73. Bachem Business Overview

Table 74. Bachem Peptide CDMO Product

Table 75. Bachem Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 76. Bachem Recent Developments

Table 77. ScinoPharm Company Details

Table 78. ScinoPharm Business Overview

Table 79. ScinoPharm Peptide CDMO Product

Table 80. ScinoPharm Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 81. ScinoPharm Recent Developments

Table 82. CBL Company Details

Table 83. CBL Business Overview

Table 84. CBL Peptide CDMO Product

Table 85. CBL Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 86. CBL Recent Developments

Table 87. AmbioPharm Company Details

Table 88. AmbioPharm Business Overview

Table 89. AmbioPharm Peptide CDMO Product

Table 90. AmbioPharm Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 91. AmbioPharm Recent Developments

Table 92. Piramal Pharma Company Details

Table 93. Piramal Pharma Business Overview

Table 94. Piramal Pharma Peptide CDMO Product

Table 95. Piramal Pharma Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 96. Piramal Pharma Recent Developments

Table 97. CordenPharma Company Details

Table 98. CordenPharma Business Overview

Table 99. CordenPharma Peptide CDMO Product

Table 100. CordenPharma Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 101. CordenPharma Recent Developments

Table 102. CPC SCIENTIFIC Company Details

Table 103. CPC SCIENTIFIC Business Overview

Table 104. CPC SCIENTIFIC Peptide CDMO Product

Table 105. CPC SCIENTIFIC Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 106. CPC SCIENTIFIC Recent Developments

Table 107. Provepharm Company Details

Table 108. Provepharm Business Overview

Table 109. Provepharm Peptide CDMO Product

Table 110. Provepharm Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 111. Provepharm Recent Developments

Table 112. Space Peptides Company Details

Table 113. Space Peptides Business Overview

Table 114. Space Peptides Peptide CDMO Product

Table 115. Space Peptides Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 116. Space Peptides Recent Developments

Table 117. Biopeptek Company Details

Table 118. Biopeptek Business Overview

Table 119. Biopeptek Peptide CDMO Product

Table 120. Biopeptek Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 121. Biopeptek Recent Developments

Table 122. Alpha Biophama Company Details

Table 123. Alpha Biophama Business Overview

Table 124. Alpha Biophama Peptide CDMO Product

Table 125. Alpha Biophama Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 126. Alpha Biophama Recent Developments

Table 127. Alabiochem Company Details

Table 128. Alabiochem Business Overview

Table 129. Alabiochem Peptide CDMO Product

Table 130. Alabiochem Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 131. Alabiochem Recent Developments

Table 132. Aurigene Pharmaceutical Services Company Details

Table 133. Aurigene Pharmaceutical Services Business Overview

Table 134. Aurigene Pharmaceutical Services Peptide CDMO Product

Table 135. Aurigene Pharmaceutical Services Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 136. Aurigene Pharmaceutical Services Recent Developments

Table 137. Chengdu Shengnuo Biotechnology Co., Ltd Company Details

Table 138. Chengdu Shengnuo Biotechnology Co., Ltd Business Overview

Table 139. Chengdu Shengnuo Biotechnology Co., Ltd Peptide CDMO Product

Table 140. Chengdu Shengnuo Biotechnology Co., Ltd Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 141. Chengdu Shengnuo Biotechnology Co., Ltd Recent Developments

Table 142. Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Company Details

Table 143. Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Business Overview

Table 144. Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Peptide CDMO Product

Table 145. Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Revenue in Peptide CDMO Business (2017-2022) & (US$ Million)

Table 146. Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Recent Developments

Table 147. Research Programs/Design for This Report

Table 148. Key Data Information from Secondary Sources

Table 149. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Peptide CDMO Market Share by Type: 2021 VS 2028

Figure 2. LPPS Features

Figure 3. SPPS Features

Figure 4. Mixed Phase Features

Figure 5. Global Peptide CDMO Market Share by Application: 2021 VS 2028

Figure 6. Pharmaceutical Industry Case Studies

Figure 7. Cosmetics Industry Case Studies

Figure 8. Others Case Studies

Figure 9. Peptide CDMO Report Years Considered

Figure 10. Global Peptide CDMO Market Size (US$ Million), Year-over-Year: 2017-2028

Figure 11. Global Peptide CDMO Market Size, (US$ Million), 2017 VS 2021 VS 2028

Figure 12. Global Peptide CDMO Market Share by Region: 2021 VS 2028

Figure 13. Global Peptide CDMO Market Share by Players in 2021

Figure 14. Global Top Peptide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO as of 2021)

Figure 15. The Top 10 and 5 Players Market Share by Peptide CDMO Revenue in 2021

Figure 16. North America Peptide CDMO Market Size YoY (2017-2028) & (US$ Million)

Figure 17. North America Peptide CDMO Market Size Market Share by Type (2017-2028)

Figure 18. North America Peptide CDMO Market Size Market Share by Application (2017-2028)

Figure 19. North America Peptide CDMO Market Size Share by Country (2017-2028)

Figure 20. United States Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 21. Canada Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 22. Europe Peptide CDMO Market Size YoY (2017-2028) & (US$ Million)

Figure 23. Europe Peptide CDMO Market Size Market Share by Type (2017-2028)

Figure 24. Europe Peptide CDMO Market Size Market Share by Application (2017-2028)

Figure 25. Europe Peptide CDMO Market Size Share by Country (2017-2028)

Figure 26. Germany Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 27. France Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 28. U.K. Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 29. Italy Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 30. Russia Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 31. Nordic Countries Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 32. Asia-Pacific Peptide CDMO Market Size YoY (2017-2028) & (US$ Million)

Figure 33. Asia Pacific Peptide CDMO Market Size Market Share by Type (2017-2028)

Figure 34. Asia Pacific Peptide CDMO Market Size Market Share by Application (2017-2028)

Figure 35. Asia Pacific Peptide CDMO Market Size Share by Region (2017-2028)

Figure 36. China Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 37. Japan Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 38. South Korea Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 39. Southeast Asia Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 40. India Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 41. Australia Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

Figure 42. Latin America Peptide CDMO Market Size YoY (2017-2028) & (US$ Million)

Figure 43. Latin America Peptide CDMO Market Size Market Share by Type (2017-2028)

Figure 44. Latin America Peptide CDMO Market Size Market Share by Application (2017-2028)

Figure 45. Latin America Peptide CDMO Market Size Share by Country (2017-2028)

Figure 46. Mexico Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 47. Brazil Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 48. Middle East & Africa Peptide CDMO Market Size YoY (2017-2028) & (US$ Million)

Figure 49. Middle East and Africa Peptide CDMO Market Size Market Share by Type (2017-2028)

Figure 50. Middle East and Africa Peptide CDMO Market Size Market Share by Application (2017-2028)

Figure 51. Middle East and Africa Peptide CDMO Market Size Share by Country (2017-2028)

Figure 52. Turkey Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 53. Saudi Arabia Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 54. UAE Peptide CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 55. Thermo Fisher Pharma Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 56. PolyPeptide Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 57. Bachem Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 58. ScinoPharm Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 59. CBL Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 60. AmbioPharm Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 61. Piramal Pharma Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 62. CordenPharma Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 63. CPC SCIENTIFIC Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 64. Provepharm Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 65. Space Peptides Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 66. Biopeptek Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 67. Alpha Biophama Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 68. Alabiochem Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 69. Aurigene Pharmaceutical Services Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 70. Chengdu Shengnuo Biotechnology Co., Ltd Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 71. Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd Revenue Growth Rate in Peptide CDMO Business (2017-2022)

Figure 72. Bottom-up and Top-down Approaches for This Report

Figure 73. Data Triangulation

Figure 74. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (10% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

CDMO Market

Global Peptide CDMO Market Insights, Forecast to 2028

Published Date: February 2022

Report Code: QYRE-Auto-26H6267

Global Peptide CDMO Market Insights, Forecast to 2028

FEATURED COMPANIES

Petide CDMO Size

Trends Influencing the Global Petide CDMO Market

Petide CDMO Market Share

By Type

By Application

By Company

By Region

FEATURED COMPANIES

FEATURED COMPANIES

HAVE A QUERY?

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-5Q14261

Fri Nov 22 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-38W13955

Fri Nov 22 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-30U13946

Fri Nov 22 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-23N13862

Fri Nov 22 00:00:00 UTC 2024

Support Contacts

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

POLICIES

THE COMPANY

CUSTOMER SUPPORT

OUR PRODUCTS

POLICES

Copyright © 2018 Valuates.com. All Rights Reserved.

Sitemap - Privacy Policy - Terms & Conditions